Warburg Effect

Warburg Effect refers to the metabolic phenomenon where cancer cells preferentially generate energy through aerobic glycolysis, converting glucose to lactate even in the presence of sufficient oxygen, rather than relying primarily on oxidative phosphorylation. This altered metabolism supports rapid cell proliferation by providing both energy and metabolic intermediates required for biosynthesis. The Warburg effect is considered a hallmark of many cancers reflecting broader metabolic reprogramming driven by oncogenic signalling.

The biopharmaceutical industry studies the Warburg effect for its implications in cancer biology, diagnostic imaging, and therapeutic targeting. Increased glucose uptake associated with aerobic glycolysis underpins FDG-PET imaging, where radiolabelled glucose analogues accumulate in metabolically active tumours. Therapeutic strategies aim to exploit metabolic dependencies by targeting glycolytic enzymes, lactate transporters, or regulators of metabolic switching such as PI3K/AKT/mTOR pathways. Tumour acidity driven by lactate accumulation can influence immune suppression and drug penetration, making metabolic modulation relevant for combination strategies with immunotherapies and targeted agents. Despite its importance, the Warburg effect is not universal across all cancers, with metabolic phenotypes varying based on tumour type, genetic drivers, and microenvironmental factors.